Publications by authors named "Ike Ogbaa"
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ETR).
View Article and Find Full Text PDFBackground: The nonsteroidal mineralocorticoid receptor antagonist finerenone and the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) canagliflozin reduce cardiorenal risk in albuminuric patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). At first glance, the results of Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) (ClinicalTrials.gov, NCT02540993) and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) appear disparate.
View Article and Find Full Text PDFIntroduction: To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Research Design And Methods: This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Article Synopsis
- Study assessed LX4211, a drug targeting SGLT1 and SGLT2, for safety and effectiveness in type 2 diabetes patients with kidney issues.
- Thirty-one participants with low kidney function received either LX4211 or placebo for 7 days, measuring various glucose levels and other health markers.
- LX4211 significantly improved postprandial and fasting glucose levels, with positive effects on glucagon-like peptide 1 levels and urinary glucose excretion, suggesting it may benefit those with type 2 diabetes and renal impairment.
Article Synopsis
- The study evaluated the effectiveness and safety of LX4211, a drug that inhibits SGLT1 and SGLT2, in type 2 diabetes patients who were not well-controlled on metformin.
- Participants were randomly assigned to different doses of LX4211 or a placebo, with the main goal of measuring changes in A1C levels after 12 weeks.
- Results showed that LX4211 significantly lowered A1C levels, reduced body weight and systolic blood pressure, and had mild side effects similar to placebo, making it a promising treatment option.
Article Synopsis
- LX4211 is a new medication that inhibits two glucose transporters, SGLT1 and SGLT2, which play key roles in glucose absorption and reabsorption in the body, impacting blood sugar levels and hormone release.
- The study aimed to find out how the timing of LX4211 doses in relation to meals affects its effectiveness on glucose levels and hormone release in twelve healthy participants.
- Results showed that taking LX4211 right before breakfast led to the best outcomes in controlling blood sugar and increasing beneficial hormones, with the treatment being well tolerated and no adverse effects like diarrhea reported.
Article Synopsis
- SGLT1 and SGLT2 are key transporters for glucose absorption in the intestines and kidneys, respectively, and LX4211 is a new drug that inhibits both to lower glucose levels.
- The study involves a phase 2 clinical trial to assess LX4211's safety and effectiveness in type 2 diabetes patients who aren't well-controlled on metformin alone.
- The main goal is to measure changes in glycated hemoglobin A1c over 12 weeks, with secondary goals looking at fasting glucose, body weight, blood pressure, and safety concerns like hypoglycemia and GI issues.
Article Synopsis
- Combination therapy for type 2 diabetes may improve glycemic control by using sodium-dependent glucose transporter (SGLT)-1 inhibitors alongside DPP-4 inhibitors to enhance GLP-1 levels.
- A study compared the effects of LX4211 and sitagliptin, both individually and together, on various hormones and glucose levels in mice and patients with T2DM.
- Results showed a synergistic effect in mice and increased levels of active GLP-1 and PYY in the combination therapy group, suggesting this approach could be effective for managing diabetes.